{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:16:58Z","timestamp":1791231418216,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Female breast and five gynecological cancers remain substantial burden in China and worldwide. GLOBOCAN 2022\u00a0has recently updated the estimates of cancer burden. This study aims to depict the profiles of disease burden and to compare the age-specific rates of female breast and five gynecological cancers in China with those in other countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The latest estimates of incidence and mortality of female breast and five gynecological cancers from various regions and countries were extracted from the GLOBOCAN 2022\u00a0database. We compared the proportion of total cases or deaths for cancers affecting female breast and five gynecological cancers and other tumor types in China and globally. Correlation analysis was conducted to evaluate the relationship between age-standardized incidence rate (ASIR) or age-standardized mortality rate (ASMR) and the Human Development Index (HDI). Additionally, age-specific rate curves were plotted for ten exemplary countries with different income levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Female breast and five gynecological cancers in China accounted for 30.2% of all newly diagnosed cancer cases. Breast cancer and cervical cancer are the most commonly diagnosed, with nearly 507,000 new cases, representing 23.48% of the new cases. The incidence rates of breast, uterine corpus, ovarian, and vulvar cancers were positively associated with HDI tiers. Chinese women aged 50\u2013\t54 years are experiencing high incidence rates of breast, cervix uteri, corpus uteri, and ovarian cancers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Female breast and five gynecological cancers continue to be a significant health concern for women in China and worldwide. It is crucial to implement comprehensive prevention strategies tailored to address the increasing trend among younger individuals and reduce regional disparities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003293","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:00:30Z","timestamp":1724904030000},"page":"2190-2201","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Burden of female breast and five gynecological cancers in China and worldwide"],"prefix":"10.1097","volume":"137","author":[{"given":"Nuopei","family":"Tan","sequence":"first","affiliation":[{"name":"Office of Cancer Screening, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Office of Cancer Screening, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2023.01.035","article-title":"Financial toxicity: A practical review for gynecologic oncology teams to understand and address patient-level financial burdens","volume":"170","author":"Liang","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"110269","DOI":"10.1016\/j.radonc.2024.110269","article-title":"Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes","volume":"195","author":"Isohashi","year":"2024","journal-title":"Radiother Oncol"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(23)00066-9","article-title":"Prevalence of human papillomavirus DNA and p16(INK4a) positivity in vulvar cancer and vulvar intraepithelial neoplasia: A systematic review and meta-analysis","volume":"24","author":"Li","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"R5-20250602","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ijgo.13867","article-title":"Cancer of the vagina: 2021 update","volume":"155","author":"Adams","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","article-title":"The global burden of women\u2019s cancers: A grand challenge in global health","volume":"389","author":"Ginsburg","year":"2017","journal-title":"Lancet"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"195","DOI":"10.46234\/ccdcw2024.040","article-title":"Incidence and mortality of cancers in female genital organs \u2013 China, 2022","volume":"6","author":"Sun","year":"2024","journal-title":"China CDC Wkly"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005\u201320: An analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"e055470","DOI":"10.1136\/bmjopen-2021-055470","article-title":"Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: An international comparative study based on the Global Burden of Disease","volume":"12","author":"Yang","year":"2022","journal-title":"BMJ Open"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"179","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019\u00a0ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R16-20250602","first-page":"E174","article-title":"Worldwide incidence and mortality of ovarian cancer and Human Development Index (HDI): GLOBOCAN sources and methods 2018","volume":"62","author":"Khazaei","year":"2021","journal-title":"J Prev Med Hyg"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5468\/ogs.2020.63.2.141","article-title":"Association between the incidence and mortality rates for corpus uteri cancer and Human Development Index (HDI): A global ecological study","volume":"63","author":"Khazaei","year":"2020","journal-title":"Obstet Gynecol Sci"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/ijc.34655","article-title":"Global incidence, risk factors and trends of vulvar cancer: A country-based analysis of cancer registries","volume":"153","author":"Huang","year":"2023","journal-title":"Int J Cancer"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.12669\/pjms.296.3788","article-title":"Age-specific incidence rate change at breast Cancer and its different histopathologic subtypes in Iran and Western countries","volume":"29","author":"Hosseini","year":"2013","journal-title":"Pak J Med Sci"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jamaoncol.2019.0620","article-title":"Insights into breast cancer in the east vs the west: A review","volume":"5","author":"Yap","year":"2019","journal-title":"JAMA Oncol"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-023-01957-3","article-title":"Epidemiological trends and risk factors of gynecological cancers: An update","volume":"40","author":"Keyvani","year":"2023","journal-title":"Med Oncol"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2\u00a0mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"14673","DOI":"10.3390\/ijms241914673","article-title":"Estrogens, estrogen receptors and tumor microenvironment in ovarian cancer","volume":"24","author":"Kozie\u0142","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"900","DOI":"10.20892\/j.issn.2095-3941.2020.0523","article-title":"Breast cancer incidence and mortality in women in China: Temporal trends and projections to 2030","volume":"18","author":"Lei","year":"2021","journal-title":"Cancer Biol Med"},{"key":"R26-20250602","first-page":"34","article-title":"Age-period-cohort analysis of trends of breast cancer incidence and mortality among Chinese females from 1990 to 2019","volume":"26","author":"Xuewei","year":"2023","journal-title":"Chin Gen Pract"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp0708307","article-title":"\u201cWesternizing\u201d women\u2019s risks? Breast cancer in lower-income countries","volume":"358","author":"Porter","year":"2008","journal-title":"N Engl J Med"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/ijc.34002","article-title":"Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020","volume":"151","author":"Cabasag","year":"2022","journal-title":"Int J Cancer"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(20)30398-3","article-title":"Effect of mammographic screening from age 40 years on breast cancer mortality (UK age trial): Final results of a randomised, controlled trial","volume":"21","author":"Duffy","year":"2020","journal-title":"Lancet Oncol"},{"key":"R31-20250602","first-page":"387","article-title":"Expert consensus on the diagnosis and treatment of young breast cancer in China (2022 Edition) (in Chinese)","volume":"103","year":"2023","journal-title":"Natl Med J China"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.2015.12783","article-title":"Breast cancer screening for women at average risk: 2015\u00a0guideline update from the American Cancer Society","volume":"314","author":"Oeffinger","year":"2015","journal-title":"JAMA"},{"issue":"Suppl 1","key":"R33-20250602","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ijgo.13882","article-title":"FIGO cancer report 2021","volume":"155","author":"Kehoe","year":"2021","journal-title":"Int J Gynecol Obstet"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jncc.2022.01.002","article-title":"Incidence and mortality of cervical cancer in China in 2015","volume":"2","author":"Gu","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R36-20250602","first-page":"213","article-title":"Cervical cancer prevention in China: Where are we now, and what\u2019s next?","volume":"21","author":"Yan","year":"2024","journal-title":"Cancer Biol Med"}],"updated-by":[{"DOI":"10.1097\/cm9.0000000000003382","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000}}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:01:18Z","timestamp":1748890878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003293","relation":{"correction":[{"id-type":"doi","id":"10.1097\/CM9.0000000000003382","asserted-by":"object"}]},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"2024-05-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}